Currently, a few phase I/II studies are ongoing to evaluate pimasertib in the setting of advanced or metastatic solid tumors including ovarian cancer, NRAS-mutated cutaneous melanoma, ovarian cancer, breast cancer, NSCLC, hepatocellular carcinoma, metastatic colorectal cancer, and pancreatic adenocarcinoma. Here, NRAS is linked to cutaneous melanoma.